Indirect evidence of the important role of EAT adipocytes’ insulin resistance in the formation of cardiovascular disease is provided by the fact that pharmacological increase in the sensitivity of adipocytes to glucose, induced by the sodium glucose cotransporter-2 inhibitor (SGLT2) dapagliflozin [41], reduces the risk of adverse cardiovascular events in patients with type 2 diabetes mellitus [42]. Here, SLC5A2 is linked to diabetes mellitus.